{"blog": [], "keywords": [{"value": "Muscular Dystrophy", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "2", "is_major": "Y"}, {"value": "Drugs (Pharmaceuticals)", "name": "subject", "rank": "3", "is_major": "N"}, {"value": "Clinical Trials", "name": "subject", "rank": "4", "is_major": "N"}, {"value": "Sarepta Therapeutics Inc.", "name": "organizations", "rank": "5", "is_major": "N"}], "web_url": "http://www.nytimes.com/2016/04/26/business/muscular-dystrophy-drug-fda-sarepta-eteplirsen.html", "document_type": "article", "byline": {"person": [{"lastname": "POLLACK", "firstname": "Andrew", "role": "reported", "organization": "", "rank": 1}], "original": "By ANDREW POLLACK"}, "type_of_material": "News", "multimedia": [{"url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbWide.jpg", "legacy": {"wide": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "subtype": "wide", "type": "image", "width": 190, "height": 126}, {"url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/26/business/26MUSCLE/26MUSCLE-articleLarge.jpg", "xlargeheight": "569", "xlargewidth": "600"}, "subtype": "xlarge", "type": "image", "width": 600, "height": 569}, {"url": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/26/business/26MUSCLE/26MUSCLE-thumbStandard.jpg", "thumbnailheight": "75", "thumbnailwidth": "75"}, "subtype": "thumbnail", "type": "image", "width": 75, "height": 75}], "section_name": "Business Day", "word_count": "1256", "source": "The New York Times", "subsection_name": null, "lead_paragraph": "The staff of the F.D.A. said a clinical trial for the drug was too small, but advocates said the drug prolonged patients\u2019 ability to walk.", "pub_date": "2016-04-26T00:00:00Z", "news_desk": "Business", "headline": {"print_headline": "F.D.A. Advisers Rebuff Muscular Dystrophy Drug", "main": "Advisers to F.D.A. Vote Against Duchenne Muscular Dystrophy Drug"}, "print_page": "1", "snippet": "The staff of the F.D.A. said a clinical trial for the drug was too small, but advocates said the drug prolonged patients\u2019 ability to walk.", "_id": "571e806e38f0d866887370f9", "slideshow_credits": null, "abstract": null}